Showing 111-120 of 4007 results for "".
2017 Tax Cuts and Jobs Act: What You Need to Know
https://practicaldermatology.com/topics/practice-management/2017-tax-cuts-and-jobs-act-what-you-need-to-know--vmyiwowa/18348/OJM Group principal Carole Foos, CPA provides an overview of the Tax Cuts and Jobs Act, which was signed in to law at the end of 2017. She discusses key provisions affecting individual physicians and medical practices, and offers advice to consider when planning for 2018 and beyond. Click here to reTips for dealing with patients and the media offered by Dr. Joel Schlessinger
https://practicaldermatology.com/topics/practice-management/tips-for-dealing-with-patients-and-the-media-offered-by-dr-joel-schlessinger/19155/In an increasingly connected world, business professionals must be aware of how negative customer experiences can quickly and easily be shared through the internet and social media. Dermatology is no different and Dr. Joel Schlessinger has heard of many cases in which a practice's reputation has sufSCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. James Q. Del Rosso on Innovative Therapies
https://practicaldermatology.com/error/404/James Q. Del Rosso, DO, joins Joel Cohen, MD, to discuss innovation in the world of acne and rosacea, atopic dermatitis, psoriasis, alopecia areata, hidradenitis suppurativa, vitiligo, and more at Music City SCALE.SCALE 2024: Dr. Joel Cohen Interviews Dr. Saranya Wyles on Exosomes
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-joel-cohen-interviews-dr-saranya-wyles-exosomes/26364/Saranya Wyles, MD, PhD, joins Joel Cohen, MD, to discuss her research on exosomes at Music City SCALE.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pClinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.Juvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.Dermatologists Push Back on Wall Street Journal Characterization
https://practicaldermatology.com/issues/january-february-2025/dermatologists-push-back-on-wsj-characterization/32900/Four-day workweeks, double the salary of some colleagues and no emails at night—those were the reasons a Wall Street Journal article concluded that medical residency applications for dermatology slots are up 50% over the past 5 years. Practical Dermatology reached out to dermatologists to get theirNoah Worcester 2024: Dr. Jogi on Hair Loss
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-jogi-hair-loss/24590/Joel L. Cohen, MD, FAAD, interviews Reena Jogi, MD about her lecture on hair loss and platelet-rich plasma at the 2024 Noah Worcester Dermatological Society meeting.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects s